|1.||Yamashita, Naoyuki: 6 articles (07/2015 - 01/2010)|
|2.||Tanaka, Hiroaki: 6 articles (07/2015 - 01/2010)|
|3.||Rayner, Craig R: 5 articles (11/2015 - 06/2007)|
|4.||Nakada, Norihide: 5 articles (07/2015 - 01/2010)|
|5.||Järhult, Josef D: 5 articles (04/2015 - 01/2011)|
|6.||Azuma, Takashi: 4 articles (07/2015 - 12/2012)|
|7.||Olsen, Björn: 4 articles (04/2015 - 01/2011)|
|8.||Söderström, Hanna: 4 articles (04/2015 - 01/2011)|
|9.||Barr, Ian G: 4 articles (09/2004 - 01/2003)|
|10.||Hampson, Alan W: 4 articles (09/2004 - 01/2003)|
|1.||Human Influenza (Influenza)
01/01/2012 - "Previous studies have indicated that the pharmaceutically active metabolite of OP, oseltamivir carboxylate (OC), is not readily degraded in sewage treatment plants (STPs) and therefore will be released into receiving waters in elevated concentrations during a pandemic outbreak of influenza. "
05/01/2013 - "Oseltamivir carboxylate (OC) has been detected in environmental waters at various levels during recent influenza seasons in humans, reflecting levels of usage and stability of this drug. "
07/01/2012 - "Premature neonates treated with 1 mg/kg and term babies treated with 2 mg/kg should have average oseltamivir carboxylate concentrations in a range similar to that for adults treated with 75 mg, corresponding to >200-fold above the half-maximal inhibitory concentration (IC(50)) value for influenza A(H1N1) from the start of therapy."
01/01/2012 - "The active metabolite oseltamivir carboxylate (OC) is not degraded in surface water or sewage treatment plants and has been detected in river water during seasonal influenza outbreaks. "
11/01/2010 - "A formal correlation between systemic exposure to oseltamivir carboxylate and clinical antiviral activity or tolerance in influenza patients has not yet been demonstrated; thus no formal therapeutic or toxic range can be proposed. "
|2.||Influenza in Birds (Avian Flu)
11/01/2015 - "Use of embryonated chicken egg as a model to study the susceptibility of avian influenza H9N2 viruses to oseltamivir carboxylate."
05/01/2013 - "Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks."
11/01/2004 - "To test whether NA could also facilitate virus entry into cell, we infected cultures of human airway epithelium with human and avian influenza viruses in the presence of the NA inhibitor oseltamivir carboxylate. "
11/01/2008 - "Since the efficacy of oseltamivir carboxylate (OC) as the active metabolite of Tamiflu has been demonstrated against influenza viruses and even against the avian influenza virus (H5N1), millions of Tamiflu treatment courses are stockpiled worldwide. "
08/01/2009 - "Oseltamivir (O), an ethyl ester prodrug of oseltamivir carboxylate (OC), is currently the drug of choice for avian influenza. "
04/01/2010 - "Oseltamivir carboxylate has high bioavailability and penetrates sites of infection at concentrations that are sufficient to inhibit viral replication. "
06/01/2009 - "Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system."
06/01/2002 - "Parallel passaging experiments were conducted with oseltamivir carboxylate, the active form of a currently marketed oral agent for the treatment of influenza virus infections. "
03/01/2001 - "Its potency and that of oseltamivir carboxylate decreased with increasing multiplicity of virus infection. "
08/01/2002 - "The emergence of virus resistant to oseltamivir carboxylate in the treatment of naturally acquired influenza infection is low (about 1%). "
09/01/2008 - "The study drugs were generally well tolerated, except for one case of reversible grade 4 thrombocytopenia in a subject in group 2. The calculated 90% confidence intervals (CIs) for the geometric mean ratios between groups 2 and 3 and group 1 were outside the bioequivalence criteria boundary (0.80 to 1.25) at 0.63 to 0.89 for group 2 versus group 1 and 0.57 to 0.90 for group 3 versus group 1. The steady-state apparent oral clearance of oseltamivir carboxylate was significantly less in groups 2 (7.4 liters/h; 90% CI, 6.08 to 8.71) and 3 (7.19 liters/h; 90% CI, 6.41 to 7.98) than in group 1 (9.75 liters/h; 90% CI, 6.91 to 12.60) (P < 0.05 for both comparisons by analysis of variance). "
|5.||Critical Illness (Critically Ill)
05/01/2013 - "Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique."
01/01/2013 - "The median (range) steady state volume of distribution of oseltamivir carboxylate was 179 (61-436) litres, much greater than healthy adults but similar to previous reports in critically ill patients. "
01/01/2011 - "High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit."
04/01/2012 - "Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza."
12/01/2012 - "Although the optimal pharmacokinetic-pharmacodynamic targets for oseltamivir carboxylate remain unclear, in the patients receiving CVVHD with or without ECMO, a regimen of oseltamivir 150 mg every 12 hours yielded a median oseltamivir carboxylate AUC(0-12) considerably higher than would be expected in non-critically ill patients receiving the same dosage regimen."
|10.||Antiviral Agents (Antivirals)
|1.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
|2.||Extracorporeal Membrane Oxygenation (ECMO)
|4.||Renal Dialysis (Hemodialysis)